3[2]Ortona l,antinori a. Principles of therapy for tuberculosis[J]. Rays. 1998;23(1): 181 ～ 92.
4[6]World health organization. treatment of tuberculosis[J].Third edition.geneva.2003,39 ～ 45.
5[7]Crowle aj, elkins n, may mh. Effectiveness of ofloxacin against m.tuberculosis and m. Avium, and rifapin against m.tuberculosis in cultured human macrophages[J]. Am rev respir dis, 1990, 137:1141 ～ 1146.
6[8]Hong kong chest service/british medical research council.A controlled study of rifabutin and uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin[J]. Tuber lung dis, 1992,73:59 ～ 67.
7[9]Young ls. et al. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria[J]. Am j med,1987,10:341.
8[10]O'buien rj, lyle ma, snider de. Rifabutin(anssamycin lm427). A new rifamycin-s derivative for the treatment of mycobacterial diseases[J]. Rev infect dis, 1987, 9:519～530.
9[11]Hidaka t. Current status and perspectives on the development of rifamycin derivative antibiotics[J].Kekkaku. 1999,74(1): 53 ～ 61.
10[12]Ji b, lounis n, maslo c, et al. Invitro and in vivo activities of moxifloxacin and clinafloxacin against mycobacterium tuberculosis[J].Antimicrob agents chemother, 1998,42:2066～ 2069.
3Gandhi NR,Moll A,Sturm AW. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa[J].{H}LANCET,2006,(9547):1575-1580.
4Cox H,Kebede Y,Allamuratova S. Tuberculosis recurrence and mortality after successful treatment:impact of drug resistance[J].{H}PLOS MEDICINE,2006,(10):384.
5Devasia RA,Blackman A,Gebretsadik T. Fluoroquinolone resistance in Mycobacterium tuberculosis:the effect of duration and timing of fluoroquinolone exposure[J].{H}American Journal of Respiratory and Critical Care Medicine,2013,(04):365-370.
